Navigating the twilight zone of DOAC plasma monitoring
-
Published:2023-05
Issue:
Volume:225
Page:101-102
-
ISSN:0049-3848
-
Container-title:Thrombosis Research
-
language:en
-
Short-container-title:Thrombosis Research
Author:
Van der Linden Lorenz
Reference10 articles.
1. DOACs plasma levels in relation to clinical outcome. How far have we come?;Talerico;Thromb. Res.,2023
2. Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?;Chan;Am. Heart J.,2018
3. Real-world variability in dabigatran levels in patients with atrial fibrillation;Chan;J. Thromb. Haemost.,2015
4. The value and limitations of new oral anticoagulant plasma level assessments;Van der Linden;Eur. Heart J. Suppl.,2022
5. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation;Weitz;Thromb. Haemost.,2010